AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26540083
Drug: Dalfampridine extended
RxNorm normalized name: Dalfampridine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine extended release (D-ER) 10 mg twice daily
Trial: 21194006
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment to avascular retina (Group A)
Trial: 21194006
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment to avascular retina and ridge (Group B)
Trial: 21194006
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment to ridge (Group B)
Trial: 19922017
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg prednisolone daily
Trial: 25109606
Drug: Pitavastatin 2
RxNorm normalized name: PITAVASTATIN 2MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 2 mg daily + intensive lifestyle modification (LSM)
Trial: 11996957
Drug: Pitavastatin 2
RxNorm normalized name: PITAVASTATIN 2MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 2 mg daily
Trial: 21715141
Drug: Intensive bimanual
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive bimanual training (Hand‐Arm Bimanual Intensive Therapy: HABIT)
Trial: 21715141
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Constraint‐Induced Movement Therapy, CIMT)
Trial: 10749820
Drug: Carbohydrate loading
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate loading (9 g CHO/kg body mass/day)
Trial: 10749820
Drug: Placebo-controlled moderate-CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-controlled moderate-CHO diet (6 g CHO/kg body mass/day)
Trial: 9051168
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (3 sessions, one weekly for 3 weeks, stimulating Bladder 10 and Gall Bladder 20 points)
Trial: 9051168
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (17 patients treated with drugs - FANS and myorelaxing - and physiotherapy)
Trial: 1627436
Drug: Single cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single cycle of combination chemotherapy (intravenous cyclophosphamide, methotrexate, and fluorouracil)
Trial: 1627436
Drug: Single cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single cycle of combination chemotherapy
Trial: 1627436
Drug: Single cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single cycle of combination chemotherapy (in postmenopausal women with ER-negative tumors)
Trial: 1627436
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant treatment (in postmenopausal women with ER-negative tumors)
Trial: 6392047
Drug: Nicergoline (Sermion)
RxNorm normalized name: nicergoline
DrugBank: Nicergoline (DB00699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (Sermion) treatment for one year
Trial: 30782199
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + SI (sustained inflation)
Trial: 17805132
Drug: Corticotomy‐assisted orthodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotomy‐assisted orthodontic treatment
Trial: 15105223
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg preincisional and 0.2 mg/kg intraoperative S(+)‐ketamine repeated at 20‐min intervals
Trial: 11378011
Drug: Talinolol (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talinolol (titrated up to 100 mg/day starting with 12.5 mg daily)
Trial: 11378011
Drug: Talinolol (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talinolol (titrated up to 150 mg/day starting with 12.5 mg daily)
Trial: 9358933
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (specifics not provided)
Trial: 9839638
Drug: Observation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation of individual tumour response to primary medical treatment
Trial: 9110909
Drug: Selegiline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (10 mg a day)
Trial: 9110909
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (selegiline and alpha-tocopherol)
Trial: 1911319
Drug: Oral terbinafine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine, 250 mg, once daily for 2 weeks
Trial: 1911319
Drug: Placebo, once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily for 2 weeks
Trial: 30280635
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (200 mg of pembrolizumab, carboplatin, and either paclitaxel or nab-paclitaxel)
Trial: 30280635
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo plus chemotherapy (saline placebo, carboplatin, and either paclitaxel or nab-paclitaxel)
Trial: 30280635
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo plus chemotherapy
Trial: 7816407
Drug: Evening primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening primrose oil supplements
Trial: 2836259
Drug: heparin-dihydergot (HDHE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin-dihydergot (HDHE) (2 X 5000 IU heparin with 0.5 mg DHE from Days 1 to 8)
Trial: 2836259
Drug: heparin-dihydergot (HDHE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin-dihydergot (HDHE)
Trial: 24935282
Drug: FAc 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAc 0.2 μg/day
Trial: 20362397
Drug: Diazepam (benzodiazepine)
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam (benzodiazepine) in addition to mechanical physiotherapy and analgesics for 7 days
Trial: 20362397
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to mechanical physiotherapy and analgesics for 7 days
Trial: 18456901
Drug: Therapist-assisted self-administered
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-assisted self-administered parent training (SDPT+T)
Trial: 14601352
Drug: Venlafaxine XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine XL (75 mg, with potential dose doubling after 2 weeks)
Trial: 10424326
Drug: Acuvue contact
RxNorm normalized name: ketotifen Drug-Eluting Contact Lens [Acuvue Theravision]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acuvue contact lenses soaked in 0.3% eye drop solutions
Trial: 8739655
Drug: Aredia (pamidronate)
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aredia (pamidronate) 90 mg i.v. every 4 weeks
Trial: 1736944
Drug: NdYAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NdYAG laser treatment
Trial: 6496560
Drug: Hydrochlorothiazide tablets
RxNorm normalized name: Hydrochlorothiazide Tablets
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide tablets
Trial: 6496560
Drug: Maxzide tablets
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maxzide tablets
Trial: 6496560
Drug: Dyazide capsules
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dyazide capsules
Trial: 16996808
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of home blood pressure monitoring and tailored behavioral intervention
Trial: 15623574
Drug: High mannan
RxNorm normalized name: Konjac mannan
DrugBank: Konjac mannan (DB14963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High mannan binding lectin (MBL) levels (>1,000 microg/L) in the cross-sectional group (n = 987)
Trial: 9036717
Drug: Parenteral gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral gold
Trial: 7794044
Drug: Triamcinolone hexacetonide
RxNorm normalized name: Triamcinolone Hexacetonide
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone hexacetonide (THA) 20 mg in 1 ml
Trial: 7794044
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% normal saline, 1 ml)
Trial: 374428
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acetaminophen and propoxyphene
Trial: 30557562
Drug: Baloxavir marboxil
RxNorm normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baloxavir marboxil (40 mg for patients weighing <80 kg and 80 mg for patients weighing ≥80 kg)
Trial: 28592311
Drug: Green cardamom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green cardamom (500 mg capsules, three times/day for 3 months)
Trial: 28592311
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg capsules, three times/day for 3 months)
Trial: 24502675
Drug: Zirconia implants
RxNorm normalized name: zirconium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zirconia implants (Ziterion vario Z(®))
Trial: 24502675
Drug: Titanium implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium implants (Ziterion vario T(®))
Trial: 19264155
Drug: Minodronate 1
RxNorm normalized name: Minodronate
DrugBank: Minodronic acid (DB06548)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Minodronate 1 mg once a day for 12 months
Trial: 19264155
Drug: Alendronate 5
RxNorm normalized name: ALENDRONATE 5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 5 mg once a day for 12 months
Trial: 16317313
Drug: ziprasidone 80‐160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ziprasidone 80‐160 mg/day
Trial: 16317313
Drug: chlorpromazine 200‐1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chlorpromazine 200‐1200 mg/day
Trial: 8329360
Drug: Lactose-enriched products
RxNorm normalized name: lactose Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-enriched products (600 g/d)
Trial: 8329360
Drug: Mg-enriched products
RxNorm normalized name: Pyelocalyceal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg-enriched products (with added Mg)
Trial: 3525068
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment with AVCF (Adriamycin, vincristine, cyclophosphamide, and 5-fluorouracil)
Trial: 25758628
Drug: 100 μg carbetocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg carbetocin shot
Trial: 25758628
Drug: 20 IU oxytocin
RxNorm normalized name: oxytocin 20 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU oxytocin infusion
Trial: 22616615
Drug: Anastrozole and
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole and fulvestrant in combination with gefitinib
Trial: 19023831
Drug: Gain framed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gain framed messages with open label sustained-release (SR) bupropion
Trial: 19023831
Drug: Loss framed
RxNorm normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loss framed messages with open label sustained-release (SR) bupropion
Trial: 16841678
Drug: Shenfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu Injection (SI) low dose (0.3 ml/kg)
Trial: 16841678
Drug: Shenfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu Injection (SI) high dose (0.6 ml/kg)
Trial: 12636878
Drug: Once-per-cycle pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once-per-cycle pegfilgrastim 6 mg
Trial: 12636878
Drug: Daily filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily filgrastim 5 microg/kg
Trial: 12636878
Drug: Both pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Both pegfilgrastim and daily filgrastim
Trial: 10812192
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m² iv day 1, Vinorelbine 25 mg/m² iv days 1-8-15-22, Amifostine 740 mg/m² iv day 1 every 4 weeks up to six cycles
Trial: 1644464
Drug: Time of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time of starting treatment
Trial: 6509461
Drug: Indapamide (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (2.5, 5, or 10 mg once daily)
Trial: 6509461
Drug: Hydrochlorothiazide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (100 mg once daily)
Trial: 30525950
Drug: Bifidobacterium animalis
RxNorm normalized name: Bifidobacterium Animalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium animalis subsp. lactis 420™ (B420), 1010 cfu/d in 12 g microcrystalline cellulose
Trial: 30525950
Drug: Litesse® Ultra™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Litesse® Ultra™ polydextrose (LU), 12 g/day
Trial: 30525950
Drug: Litesse® Ultra™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Litesse® Ultra™ polydextrose (LU) + B420, 1010 cfu/d of B420 in 12 g/d LU
Trial: 30525950
Drug: Placebo, 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 12 g/d microcrystalline cellulose
Trial: 28834534
Drug: Electropalatography (EPG)
RxNorm normalized name: dyphylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Solution [Lufyllin-EPG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electropalatography (EPG) therapy delivered in twice-weekly 30-minute sessions for 8 weeks
Trial: 28834534
Drug: Electropalatography (EPG)
RxNorm normalized name: dyphylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Solution [Lufyllin-EPG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electropalatography (EPG) therapy
Trial: 21959071
Drug: Titrated oral
RxNorm normalized name: magnesium citrate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated oral misoprostol (20 mL of misoprostol solution 1 μg/mL orally every 1 hour for 4 doses then titrated to 40 μg every 1 hour)
Trial: 21959071
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral misoprostol (50 μg of misoprostol orally every 4 hours up to 12 hours)
Trial: 19673652
Drug: Egg-based trivalent
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg-based trivalent inactivated influenza vaccine (TIV)
Trial: 15522554
Drug: 5-year tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-year tamoxifen administration
Trial: 15522554
Drug: 2-year tamoxifen
RxNorm normalized name: tamoxifen 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-year tamoxifen administration
Trial: 11163295
Drug: Sinemet (25/250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinemet (25/250 mg)
Trial: 9692700
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg b.d.; n = 10)
Trial: 9692700
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg b.d.; n = 10)
Trial: 9692700
Drug: Pantoprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (40 mg b.d.; n = 10)
Trial: 7826791
Drug: Pethidine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine 0.75 mg kg‐1 and clonidine 75 micrograms intrathecally
Trial: 7826791
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% with morphine 0.5 mg
Trial: 7864704
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg single dose
Trial: 3293526
Drug: Ciprofloxacin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 1,000 mg (500 mg doses given 12 h apart)
Trial: 31530046
Drug: In-hospital physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital physiotherapy treatment (early mobilization, ambulation, breathing exercises, thoracic range of motion exercises)
Trial: 31530046
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not receiving in-hospital physiotherapy treatment)
Trial: 23727830
Drug: Pre-test measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-test measurement of sequential effect before manipulation phase
Trial: 23727830
Drug: Post-test measurement
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-test measurement of sequential effect after manipulation phase with increased mechanical costs
Trial: 16303817
Drug: Pulsed low-intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed low-intensity ultrasound therapy (LIUS)
Trial: 15973019
Drug: Mycobacterium tuberculosis
RxNorm normalized name: MYCOBACTERIUM TUBERCULOSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycobacterium tuberculosis H37Ra excretory‐secretory antigen (ES‐31) and affinity purified goat anti ES‐31 antibodies
Trial: 18796184
Drug: Naltrexone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (all doses)
Trial: 18796184
Drug: Naltrexone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (25 mg and 50 mg)
Trial: 16953990
Drug: Twice-daily oral
RxNorm normalized name: Ferriprox 1000 MG Twice-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily oral hygiene care with 0.12% chlorhexidine gluconate
Trial: 16953990
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral care 6 times per day with soft foam swab and half strength hydrogen peroxide
Trial: 15206694
Drug: Intermittent cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent cyclosporin A therapy
Trial: 11316172
Drug: Prazosin 2
RxNorm normalized name: prazosin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 2 mg + Terlipressin 2 mg
Trial: 11989841
Drug: Terlipressin 2
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin 2 mg
Trial: 9643160
Drug: Lacidipine 4
RxNorm normalized name: lacidipine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine 4 mg
Trial: 9643160
Drug: Lacidipine 6
RxNorm normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine 6 mg
Trial: 7609516
Drug: Lacidipine 8
RxNorm normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine 8 mg
Trial: 7609516
Drug: Lacidipine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine (all doses)
Trial: 3129313
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) pulsatile LH‐RH therapy (50 to 100 ng/kg body weight/90 to 120 minutes)
Trial: 3129313
Drug: Naloxone administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone administration (2 mg IV bolus plus 4 mg infusion lasting 120 minutes)
Trial: 23948835
Drug: Deep cross-friction
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep cross-friction treatment on the thoraco-lumbar Erector spinae and gluteals, 30 minutes, two sessions per week
Trial: 20980977
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein intake (0.58 g/kg per day)
Trial: 20980977
Drug: Usual protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual protein intake (1.3 g/kg per day)
Trial: 20980977
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low protein intake (0.28 g/kg per day)
Trial: 20980977
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein intake (0.58 g/kg per day) in study B
Trial: 12895183
Drug: Vehicle applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vehicle applied twice daily for 28 days
Trial: 12895183
Drug: Ciclopirox gel
RxNorm normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclopirox gel 0.77%
Trial: 10618300
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (n=35)
Trial: 3910771
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg twice daily (group CD)
Trial: 3910771
Drug: Previous regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous regimen (beta-blockers and diuretics) (group BD)